- Home
- ILAG vs BIAF Comparison
ILAG vs BIAF Comparison
Compare ILAG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- BIAF
- Stock Information
- Founded
- ILAG 1981
- BIAF 2014
- Country
- ILAG Hong Kong
- BIAF United States
- Employees
- ILAG N/A
- BIAF N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ILAG Consumer Discretionary
- BIAF Health Care
- Exchange
- ILAG Nasdaq
- BIAF Nasdaq
- Market Cap
- ILAG 15.9M
- BIAF 14.5M
- IPO Year
- ILAG 2022
- BIAF 2022
- Fundamental
- Price
- ILAG $0.87
- BIAF $0.94
- Analyst Decision
- ILAG
- BIAF Strong Buy
- Analyst Count
- ILAG 0
- BIAF 1
- Target Price
- ILAG N/A
- BIAF $6.00
- AVG Volume (30 Days)
- ILAG 44.2K
- BIAF 161.1K
- Earning Date
- ILAG 01-17-2025
- BIAF 11-14-2024
- Dividend Yield
- ILAG N/A
- BIAF N/A
- EPS Growth
- ILAG N/A
- BIAF N/A
- EPS
- ILAG N/A
- BIAF N/A
- Revenue
- ILAG $8,980,747.00
- BIAF $9,367,785.00
- Revenue This Year
- ILAG N/A
- BIAF $285.51
- Revenue Next Year
- ILAG N/A
- BIAF $20.05
- P/E Ratio
- ILAG N/A
- BIAF N/A
- Revenue Growth
- ILAG 33.03
- BIAF 2813.87
- 52 Week Low
- ILAG $0.33
- BIAF $0.83
- 52 Week High
- ILAG $1.35
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- ILAG 42.10
- BIAF 41.39
- Support Level
- ILAG $0.83
- BIAF $0.83
- Resistance Level
- ILAG $0.98
- BIAF $0.97
- Average True Range (ATR)
- ILAG 0.07
- BIAF 0.13
- MACD
- ILAG 0.00
- BIAF 0.01
- Stochastic Oscillator
- ILAG 30.00
- BIAF 23.75
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.